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Abstract
Background The initial 6-month data for MUSETM
(Medigus, Omer, Israel) endoscopic stapling device were
reported (Zacherl et al. in Surg Endosc 29:220–229, 2015).
The current study aims to evaluate the long-term clinical
outcome of 37 patients who received endoscopic gastroe-
sophageal reflux disease (GERD) treatment with the
MUSETM device.
Methods Efficacy and safety data for 37 patients were
analyzed at baseline, 6 months, and 4 years post-proce-
dure. In one center (IU), efficacy and safety data were
evaluated at baseline, 6 months post-procedure, and then
annually up to 4 years.
Results No new complications have been reported in our
long-term analysis. The proportions of patients who
remained off daily PPI were 83.8 % (31/37) at 6 months
and 69.4 % (25/36) at 4 years post-procedure. GERD-
Health Related Quality of Life (HRQL) scores (off PPI)
were significantly decreased from baseline to 6 months and
4 years post-procedure. The daily dosage of GERD medi-
cations, measured as omeprazole equivalents (mean ± SD,
mg), decreased from 66.1 ± 33.2 at baseline to
10.8 ± 15.9 at 6 months and 12.8 ± 19.4 at 4 years post-
procedure (P\ 0.01).
Conclusions In our multi-center prospective study, the
MUSETM stapling device appears to be safe and effective
in improving symptom scores as well as reducing PPI use
in patients with GERD. These results appeared to be equal
to or better than those of the other devices for endoluminal
GERD therapy. Future studies with larger patient series,
sham control group, and greater number of staples are
awaited.
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The aims of treatment in gastroesophageal reflux disease
(GERD) include relief of symptoms, healing of esophagitis
if present, prevention of symptom recurrence, and pre-
vention of complications such as esophageal ulcers, peptic
strictures, and Barrett’s esophagus. Both medical therapy
with antacids or proton pump inhibitors (PPI) and surgical
treatments decrease symptoms and improve the quality of
life in GERD [1–3]. Currently, acid suppression with PPI
therapy remains the most widely used treatment option,
being highly effective in symptom relief, as well as in
healing and maintaining remission [4–6]. Pharmacologic
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therapy, however, often requires long-term treatment, and
some patients are unwilling to take daily medication for
prolonged periods of time or even for lifelong. Addition-
ally, up to 40 % of patients do not have a complete
response to PPI treatment [7–10]. Surgical treatment, such
as fundoplication, is indicated when the above measures
fail or at the patient’s request. While laparoscopic fundo-
plication is the treatment of choice for the surgical treat-
ment of GERD, its inherent invasive nature as a surgical
procedure remains. As alternatives to drugs and surgery, a
number of endoscopic techniques have been developed to
treat GERD [11, 12]. The purpose of these endoscopic
procedures is to modify the gastroesophageal junction
(GEJ) to decrease reflux from the stomach into the
esophagus. Initial studies demonstrated promising clinical
results and short-term efficacies of the new endoscopic
therapies; however, the long-term follow-up results are less
often reported [11, 12].
Recently, a short-term follow-up result of endoscopic
anterior fundoplication using a novel transoral endoscopic
device (MUSETM, formerly called SRS; Medigus, Omer,
Israel) has been published and shown to be generally safe
and effective as an alternative endoscopic GERD therapy
[13]. In that report, safety and efficacy data for MUSETM
stapling device obtained from six international sites were
compared at baseline and 6 months post-procedure. The
GERD-Health Related Quality of Life (HRQL) scores (off
PPI) improved by[50 % in 73 % (48/66) of patients, and
42 patients (64.6 %) were no longer using daily PPI
medication. The mean percent of total time with esopha-
geal pH B 4.0 decreased from baseline to 6 months post-
procedure. Two severe adverse events (SAEs) requiring
intervention were reported in this study. This multi-center
prospective clinical study evaluated the long-term safety
and efficacy of endoscopic treatment with the MUSETM
endoscopic stapling device which was used to treat 37
patients with GERD. Three of the initial six centers fol-
lowed their patients for 4 years and are the subjects of this
report.
Patients and methods
The current long-term follow-up data are an extension to
the previously mentioned initial 6-month data report of the
multi-center prospective clinical trial of the MUSETM
endoscopic stapling device (identifier: NCT00734747)
[13]. Three international centers (one in Europe, one in
India and one in the USA) participated in this long-term
follow-up trial, with each site obtaining institutional review
board approval. Informed consent was obtained from all
participants.
Patients
This prospective multi-center clinical trial included
patients aged 18–70 years with C2 years of documented
GERD symptoms and C6 months of continuous PPI ther-
apy treated between May 2008 and November 2010. Full
details of the inclusion and exclusion criteria for the
enrollment of our patients were described in a previously
published report [13]. In one center (Indiana University,
abbreviated as IU), efficacy and safety data were evaluated
at baseline, 6 months post-procedure, and then annually for
4 years. Procedure safety was determined by evaluation of
all treatment-related adverse events. All data were obtained
by phone interview, mail survey, or direct patient contacts
at clinic.
Device and procedure
The full descriptions for the composition of the device (the
MUSETM endostapler, designed to be operated by a single
user) and the endostapling procedure were detailed in a
previously published report [13]. The incident deserving
special mention was the protocol amendment after the 24
cases to reduce the pressure gradient between the abdom-
inal and thoracic cavity in order to prevent air leaks around
the anchoring screws. Initially, positive end-expiratory
pressure (PEEP) of 5 mmHg (6.8 cm H2O) was applied
only to patients with a sliding hiatal hernia (SHH, patients
with SHH C 3 cm were excluded from the initial enroll-
ment). After the amendment, all subjects were ventilated
with a PEEP setting of 5 mmHg, after the orotracheal
intubation, and if SHH were still evident after the appli-
cation of 5 mmHg PEEP, PEEP was gradually increased to
10 mmHg until the hernia was reduced. The proportion of
patients with small hiatal hernia\3 cm was 21.6 % (eight
of 37 enrolled patients had reducible small hiatal hernia).
In the first 24 subjects, two serious adverse events (SAEs)
occurred, including a case of empyema and pneumothorax
due to esophageal leak and a case of upper gastrointestinal
hemorrhage. For mitigation of risk, the procedure protocol
was amended to apply additional stapling (maximum three
sets of 5 each) and to require prophylactic anti-emesis
treatment to prevent immediate post-operative retching
with the aim of reducing stress at the stapling site. The
protocol was also amended to require a chest X-ray to
confirm no leaks are present prior to hospital discharge. In
addition, device changes were made to prevent air insuf-
flation during screw insertion in order to prevent the ten-
dency of air to leak into the peritoneum around the screws
before the staples are formed. Following these amendments
and protocol changes, there were no further cases of leak or
pneumoperitoneum.
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Assessment of efficacy and safety
Enrolled patients completed the GERD-HRQL question-
naire and a medication list indicating the names, dose, and
the frequency of the anti-secretory drugs at the time points
of baseline, 6 months, 1, 2, 3, and 4 years post-procedure.
The GERD-HRQL measures were administered twice
during the pre-procedure phase: once while on PPI medi-
cation and again after having discontinued the medication
for 7 days. An upper gastrointestinal endoscopy was per-
formed at baseline to evaluate the presence and size of
hiatal hernia and the grade of esophagitis in correspon-
dence to established study inclusion criteria. Esophageal
pH monitoring was measured and manometry performed at
baseline with patients off anti-secretory medications for at
least 7 days. At month 6, patients underwent repeat eso-
phageal pH measurement, esophageal manometry, and
standard upper gastrointestinal endoscopy, after the
patients were off PPI therapy for a minimum of 7 days.
Esophageal pH measurement and manometry were not
repeated after the 6 months post-procedure. Adverse events
were evaluated at each visit of time 0, weeks 1, 4, 12,
month 6, and years 1, 2, 3, and 4 as well as at any
unscheduled visits. SAEs were defined as those that
resulted in death, were life-threatening, or required pro-
longation of a current hospitalization. Per protocol, hospi-
talization was allowed for up to 72 h following the
procedure. Hospitalization days beyond this period were
recorded as a SAE.
Statistical analysis
The safety measures and reduction in GERD-HRQL score
in total patients cohort (multi-center trial including 37
patients) and patients cohort of IU (n = 21) at the follow-
up time points were analyzed as a primary end point in this
study. The proportions of patients who were off daily PPI
medications and daily dosage measured as omeprazole
equivalents (mg) in total patients cohort and patients cohort
of IU at the follow-up time points were analyzed as sec-
ondary end points in this study. Due to the nonparametric
distribution of most of the continuous data, comparisons
between baseline and post-procedure results (reduction in
GERD-HRQL score, daily dosage of GERD medications
measured as omeprazole equivalents, total time distal
esophageal pH B 4.0, and DeMeester score) were tested by
Wilcoxon signed-rank test (2-related samples) or Kendall’s
W test (K-related samples) where appropriate, at a P value
of 0.05. Analyses of dichotomous variables (proportions of
patients who were off daily PPI medication) were per-
formed using Fisher’s exact test. Statistical analysis was
conducted using the SPSS version 13.0 software package
(SPSS Inc., Chicago, IL).
Results
Initially, 64 patients who consented and enrolled in the
initial short-term follow-up study [13] across 6 interna-
tional sites served as the population for this long-term
safety and efficacy analysis. Four-year data were collected
from only three of the six centers with 39 total patients. Of
these, 37 patients had full 4-year follow-up data (37/39).
The baseline characteristics of the total patients cohort and
IU cohort are outlined in Table 1.
Primary outcomes
After 6 months of follow-up, no new SAEs were reported
in our long-term analysis. The SAEs occurred during the
Table 1 Baseline characteristics
Characteristics Total patients cohort
(n = 37)
IU cohort
(n = 21)
P value
Age (mean ± SD, years) 44.7 ± 13.3 48.4 ± 14.7 NS
Male gender (%) 20 (54.1) 11 (52.4) NS
BMI (mean ± SD, kg/m2) 26.2 ± 4.9 28.6 ± 3.9 NS
GERD-HRQL score (mean ± SD, off PPI) 29.1 ± 5.6 30.9 ± 6.3 NS
GERD-HRQL score (mean ± SD, on PPI) 13.3 ± 6.4 13.6 ± 6.3 NS
Daily PPI use (%) 37 (100.0) 21 (100.0) NS
Daily dosage of GERD medications, measured as omeprazole equivalents
(mean ± SD, mg)
66.1 ± 33.2 80.2 ± 31.4 NS
% Time pH\ 4.0 (mean ± SD) 12.7 ± 13.2 11.2 ± 6.9 NS
DeMeester score (mean ± SD) 49.4 ± 47.2 41.1 ± 22.7 NS
IU Indiana University, SD standard deviation, NS not significant, BMI body mass index, kg kilogram, GERD-HRQL Gastroesophageal Reflux
Disease-Health Related Quality of Life, PPI proton pump inhibitor
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initial 6-month follow-up were previously reported [13].
Improvement in GERD symptoms, as measured by the
reduction in GERD-HRQL score in our total patients
group, was accomplished during the follow-up period of
4 years. The mean ± SD GERD-HRQL scores (off PPI) of
the total patients group improved from 29.1 ± 5.6 to
8.9 ± 8.3 at 6 months (P\ 0.01, compared to baseline)
and 5.3 ± 5.8 at 4 years post-procedure (P\ 0.01, com-
pared to baseline and 6 months, Fig. 1A). Annual follow-
up data obtained in one center (IU) revealed similar data
for GERD-HRQL scores (mean ± SD, off PPI) compared
to those of total patients group (Fig. 1B).
Secondary outcomes
The proportions of patients who remained off daily PPI
medication in the total patients group were 83.8 and
69.4 % at 6 months and 4 years post-procedure, respec-
tively (Fig. 2A). The proportions of patients who remained
off daily PPI medication in the IU group were similar to
those of total patients group (Fig. 2B). The daily dosage of
GERD medications, measured as omeprazole equivalents
(mean ± SD, mg), for the total patients group decreased
from 66.1 ± 33.2 at baseline to 10.8 ± 15.9 and
12.8 ± 19.4 at 6 months and 4 years post-procedure,
respectively (P\ 0.01, compared to baseline, Fig. 3A).
The daily dosage of GERD medications (mean ± SD, mg)
for IU group was also decreased similar to those for total
patients group (Fig. 3B). Although the patients remaining
on daily acid suppression therapy after 4 years of MUSE
treatment were still substantial, they had lower symptom
scores, and most had reduced dose of PPI medication. No
patient required laparoscopic Nissen fundoplication.
Improvement in acid exposure
According to the initial short-term follow-up study,
pathologic gastroesophageal acid reflux was defined as
Fig. 1 The changes in GERD-HRQL off daily PPI scores in A multi-center trial including three sites and B subset of one center (IU) with annual
follow-up data
Fig. 2 The proportions of patients who remained off daily PPI in A multi-center trial including three sites and B subset of one center (IU) with
annual follow-up data
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[4.5 % total time with pH\ 4.0 or a DeMeester com-
posite score[14.7. In the current study, 13 (37.1 %) of 35
enrolled patients (two subjects did not complete the
6-month pH study) showed normalization of their 6-month
pH study by 24- or 48-h ambulatory pH study results. Both
total patients group and IU group experienced a reduction
in acid reflux, as measured by intraesophageal pH moni-
toring administered at baseline and 6 months post-proce-
dure. The mean ± SD percent total time distal esophageal
pH B 4.0 improved from 12.7 ± 13.2 % at baseline to
7.0 ± 4.7 % at 6 months post-procedure in total patients
group (44.9 % reduction, P = 0.022, Fig. 4A). The
mean ± SD DeMeester score of the total patients group
improved from 49.4 ± 47.2 to 29.1 ± 22.0 at 6 months
post-procedure (41.1 % reduction, P = 0.028, Fig. 4C).
The mean ± SD percent total time distal esophageal
pH B 4.0 (Fig. 4B) and the mean ± SD DeMeester score
(Fig. 4D) in the IU group also improved from baseline to
6 months post-procedure. However, it did not reach sta-
tistical significance unlike the total patients group.
Discussion
In our multi-center prospective study, the MUSETM
endoscopic stapling device was shown to be relatively safe
and efficacious with more than 4 years of follow-up for
patients with PPI-responsive, moderate-to-severe GERD.
Our primary study end points were safety profiles and the
comparisons of effectiveness of MUSETM endoscopic sta-
pling device measured as reduction in GERD-HRQL score.
Most SAEs were reported in the immediate post-procedural
period and were concentrated in the first 24 subjects. The
introduction of protocol amendments as the use of anti-
retching prophylaxis, increased number of staplings, and
air insufflation control during the screw deployment
resulted in much improved safety profile in the remaining
subjects enrolled, and no additional cases of leakage or
pneumomediastinum were reported. Additionally, no new
residual SAEs have been reported in our long-term follow-
up after 6 months of this procedure.
Reduction in GERD-HRQL score by the range of
69–82 % at each time point of follow-up is comparable to
those achieved in other endoscopic therapies for GERD [11,
12, 14–16]. A reduction in GERD-HRQL scores for the NDO
Plicator (NDO Surgical, Inc., Mansfield, MA, USA) from
baseline to 36 months was reported to be 19 to 8 [14] and
similar or slightly inferior to those (29.1 to 5.3 in our total
patients group, and 30.9 to 7.3 in IU group) seen in the cur-
rent study. When compared to transoral incisionless fundo-
plication (TIF 2.0) using EsophyXTM device (EndoGastric
Solutions, Redmond, WA, USA), patients in our study had
lower GERD-HRQL scores at baseline (29.1 vs. 46) with
similar improvements at 6-month follow-up (8.9 vs. 15) [15].
Ten-year follow-up data for radiofrequency modulation of
lower esophageal sphincter or Stretta procedure [16]
showed significant decrease in GERD-HRQL scores (base-
line 27.81 to 8.55 at 10-year follow-up). Although only
4-year follow-up data were available in the current study,
decrease in the mean GERD-HRQL score (off PPI, 29.1 to
5.3 at 4 years) showed similar results to those of long-term
follow-up study for Stretta procedure [16]. Sustained
reduction in GERD-HRQL score up to 4 years was seen in
our study. So far, there have been only a few reports con-
cerning the long-term durability of therapeutic effectiveness
for endoscopic treatment of GERD [14–16].
Fig. 3 The daily dosage of GERD medication, measured as omeprazole equivalents (mg) in A multi-center trial including three sites and
B subset of one center (IU) with annual follow-up data
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The secondary end points of the current study were the
proportions of patients who were off daily PPI medications
and daily dosage of GERD medications measured as
omeprazole equivalents (mg) in total patients cohort and IU
cohort at the follow-up time points. Increases in the pro-
portion of patients off daily PPI medication were observed
in both total patients group and IU group up to 4 years after
the treatments (Fig. 2). Long-term follow-up data for NDO
Plicator14 showed similar results to the current study for the
proportion of patients off daily PPI medication and
revealed that 57 % (16/28) of baseline PPI-dependent
patients remained off daily PPI therapy. For the Eso-
phyXTM device [15], mid-term (2 years) proportion of
patients off daily PPI (69.2 % in EsophyXTM vs. 72.2 % in
the IU group of the current study) also revealed similar
results to the current study. Ten-year follow-up data for
Stretta procedure [16] showed that 50 % or greater
reduction in PPI use compared to baseline was achieved in
64 % of patients and in 41 %, PPIs were entirely
eliminated.
A reduction in daily dosage of GERD medications,
measured as omeprazole equivalents (mean ± SD, mg) up
to 4 years after the procedure, further supports durable
symptomatic improvement (Fig. 3). The similar decreases
in daily dosage of GERD medications were observed in the
studies using other endoscopic plication devices as well
[14–16].
The 44.9 % reduction in the mean total time distal
esophageal pH B 4.0 in total patients group at 6 months
after the procedure was seen (P = 0.52 vs. baseline). This
trend was superior to data (15.8 %) reported in NDO Pli-
cator study. The 41.1 % reduction in the mean DeMeester
score in total patients group at 6 months after the procedure
was also superior to data (15.9 %) reported in NDO Pli-
cator study [14]. The pH monitoring data obtained
6 months after transoral incisionless fundoplication (TIF
2.0) with EsophyXTM also showed similar results to our
study [15]. The percentage of reflux episodes reaching the
proximal esophagus tended to be lower, but there was no
difference in the number of weakly alkaline refluxes. The
number of weakly acidic refluxes decreased after treatment,
though not significantly. The DeMeester score also did not
change. The LES pressure and distal esophageal amplitude
did not change after treatment.
Important limitations in the design of the current study
include a small number of enrolled patients and the lack of
a sham or control group. GERD has been shown to have a
placebo response rate of at least 25 percent, as shown by
results from sham control studies [17, 18]. Subjective
improvements in outcomes such as symptoms and QOL
Fig. 4 Both total patients group and IU subset group showed a
reduction in acid reflux, as measured by wireless 48-h pH monitoring
administered at baseline and 6 months post-procedure. Percent total
time pH B 4.0 (mean ± SD) was decreased from baseline to
6 months post-procedure in A total patients group (12.7 ± 13.2 to
7.0 ± 4.7) and B IU subset group (11.2 ± 6.9 to 8.2 ± 4.0).
DeMeester scores (mean ± SD) were also decreased from baseline
to 6 months post-procedure in C total patients group (49.4 ± 47.2 to
29.1 ± 22.0) and D IU subset group (41.1 ± 22.7 to 32.5 ± 15.2)
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may not necessarily correlate with objective measurements
such as gastroesophageal acid reflux, and controversies
continue over the mode of action of various endoscopic
therapies.
In conclusion, the current multi-center prospective study
reports the long-term follow-up results of safety and ther-
apeutic effectiveness of MUSETM endoscopic stapling
device in patients with GERD. MUSETM endoscopic sta-
pling device appears to be safe and effective in improving
symptom scores as well as reducing PPI use in patients
with GERD. Further studies with longer-term follow-up
results of intraesophageal pH monitoring and with a sham
control group are awaited.
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